STOCK TITAN

Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that Dr. Zheng Wei, CEO, and Dr. Selwyn Ho, Chief Business Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on October 26, 2021, at 1:00 PM ET. A webcast of the discussion will be available on the Company's Investor Relations page, with a replay accessible afterward. Connect Biopharma focuses on developing therapies for chronic inflammatory diseases, with lead candidates CBP-201 and CBP-307 currently in clinical trials for conditions like atopic dermatitis and ulcerative colitis.

Loading...
Loading translation...
Argus Session date unavailable
+7.72% session move Open Argus
Details

News Market Reaction – CNTB

The recorded move for CNTB in the trading session of this news was +7.72%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN DIEGO, CA and TAICANG, SUZHOU, China, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, and Dr. Selwyn Ho, Chief Business Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, October 26, 2021 at 1:00 pm ET.

A webcast of this fireside chat will be available on the Company’s Investor Relations page accessible here: https://investors.connectbiopharm.com/. A replay will be available on the Company’s website following the event.

About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.

Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) and is currently being evaluated in clinical trials for the treatment of atopic dermatitis (AD), Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Our second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) that is in clinical trials for ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we have started the clinical development of CBP-174, a peripherally restricted antagonist of histamine receptor 3, for the treatment of pruritus associated with AD.

With headquarters in China, additional operations in the United States and Australia, and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com.

IR/PR CONTACTS: 
Lazar FINN Partners
David Carey (IR)
T: +1-(212) 867-1768
david.carey@finnpartners.com

Erich Sandoval (Media)
+1-(646) 871-8482 or +1-(917) 497-2867
erich.sandoval@finnpartners.com

Corporate Contacts:
info@connectpharm.com 


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date and time of Connect Biopharma's participation at the Jefferies Virtual Healthcare Conference?

Connect Biopharma will participate in the Jefferies Virtual Healthcare Conference on October 26, 2021, at 1:00 PM ET.

Where can I find the webcast of the Connect Biopharma fireside chat?

The webcast for the Connect Biopharma fireside chat can be found on the Company's Investor Relations page.

What are the lead product candidates of Connect Biopharma?

Connect Biopharma's lead product candidates are CBP-201, targeting atopic dermatitis and asthma, and CBP-307, for ulcerative colitis and Crohn's disease.

What chronic diseases does Connect Biopharma focus on treating?

Connect Biopharma focuses on treating chronic inflammatory diseases such as atopic dermatitis, asthma, and ulcerative colitis.

Who are the executives participating in the Connect Biopharma fireside chat?

Dr. Zheng Wei, CEO, and Dr. Selwyn Ho, Chief Business Officer, will participate in the fireside chat.

Keep reading